Effect of experimental diabetes on pharmacokinetic parameters of lidocaine and megx in rats

Polish Journal of Pharmacology

Volumn 55, Issue 4, 2003, Pages 619-624

  Gawrońska Szklarz, Barbara ^a   Musial, David H ^a   Pawlik, Andrzej ^a   Paprota, Bartosz ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Diabetes; Lidocaine; MEGX; Pharmacokinetics

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DEETHYLLIDOCAINE; FRUCTOSAMINE; GLUCOSE; LIDOCAINE; STREPTOZOCIN; UREA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME ACTIVITY; FRUCTOSAMINE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; NONHUMAN; RAT; STREPTOZOCIN DIABETES; UREA BLOOD LEVEL; VOLUMETRY;

ANESTHETICS, LOCAL; ANIMALS; AREA UNDER CURVE; DIABETES MELLITUS, EXPERIMENTAL; INJECTIONS, INTRAVENOUS; LIDOCAINE; MALE; METABOLIC CLEARANCE RATE; RANDOM ALLOCATION; RATS; RATS, WISTAR; TIME FACTORS;

EID: 16744365677     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Ackerman M.D., Leibman K.C.: Effect of experimental diabetes on drug metabolism in the rat. Drug Metab. Dispos., 1977, 5, 405-410.
2. Barry M,G., Collins W.C.J., Feely J.: Plasma protein binding of drugs in insulin-dependent diabetes. Brit. J. Pharmacol., 1986, 89, 719-723.
3. Botta F., Giannini E., Fasoli A., Romagnoli P., Risso D., Testa R.: The monoethylglycinexylidide test dose not impair psychometric perfomance in patiens with chronic hepatitis or cirrhosis. Ther. Drug Monit., 2000, 22, 371-374.
4. Chen Y., Potter J.M., Ravenscroft P.J.: High-performance liquid chromatographic method for the simultaneous determination of monoethylglycinexylidide and lignocaine. J. Chromatogr., 1992, 574, 361-364.
5. Coutts R.T., Torok-Both G.A., Chu L.V., Tam Y.K., Passuto F.M.: Isolation of urinary metabolites as pentafluorobenzoyl derivatives and their identification by combined gas chromatography-mass spectrometry. J. Chromatogr., 1987, 421, 267-280.
6. Di Fazio C.A., Brown R.E.: Lidocaine metabolism in normal and phenobarbital pretreated dogs. Anesthesiology, 1972, 36, 238-243.
7. Emaami J., Pasutto F.M., Jamali F.: Effect of experimental diabetes mellitus and arthritis on the pharmacokinetics of hydroxychloroquine enantiomers in rats. Pharm. Res., 1988, 15, 897-903.
8. Forest J.A.H., Finleyson N.D.C.: Adjepan-Yamoach K.K., Prescott L.F: Antipyrine, paracetamol and lignocaine elimination in chronic liver disease. Brit. Med. J., 1977, 1, 1384-1387.
9. Gatti G.: Serum protein binding of phenytoin and valproic acid in insulin-dependent diabetes mellitus. Ther. Drug Monit., 1987, 9, 389-391.
10. Gawrońska-Szklarz B., Musial D., Drozdzik M., Paprota B.: Metabolism of lidocaine by liver microsomes from streptozotocin-diabetic rats. Pol. J. Pharmacol., 2003, 55, 251-254.
11. Higaki K., Matsumoto Y., Fujimoto R., Kurosaki Y., Kimura T.: Pharmacokinetics of recombinant human insulin-like growth factor-I in diabetic rats. Drug Metab. Dispos., 1997, 25, 1324-1327.
12. Higaki K., Matsumoto Y., Fujimoto R., Kurosaki Y., Kimura T.: Developmental changes in pharmacokinetics of recombinant human insulin-like growth factor-I in rats. Res. Commun. Mol. Pathol. Pharmacol., 1997, 97, 115-124.
13. Kaplowitz N.: Physiological significance of glutathione S-transferase. Amer. J. Physiol., 1980, 239, 639-644.
14. Kato R., Gillette J.R.: Sex differences in the effects of abnormal physiological states on the metabolism of drugs by the rat liver microsomes. J. Pharmacol. Exp. Ther., 1965, 150, 285-291.
15. Kato R., Takanaka A., Onoda K.: Species and sex difference in aminopyrine N-demethylating activity of liver microsomes under unphysiological conditions. Jpn. J. Pharmacol., 1968, 18, 516-517.
16. Kawai R., Fujits S., Suzuki T.: Simultaneous quantitation of lidocaine and its four metabolites by high-performance liquid chromatography: Application to studies on in vitro and in vivo metabolism of lidocaine in rats. J. Pharm. Sci., 1985, 74, 1219-1224.
17. Kearns G.L., Kemp S.F., Thurley C.P., Nelson O.L.: Protein binding of phenytoin and lidocaine in pediatric patients with type I diabetes mellitus. Develop. Pharm. Ther., 1998, 11, 14-23.
18. Lewis D.F., Pratt J.M.: The P-450 catalytic cycle and oxygenation mechanism. Drug Metab. Rev., 1998, 30, 739-786.
19. Miller L.L., Treat D.E., Fridd B., Weniett D.: Effects of streptozotocin diabetes in the rat on blood levels of ten specific plasma proteins and on their net biosynthesis by the isolated perfused liver. Hepatology, 1990, 11, 635-45.
20. Oda Y., Imaoka S., Nakahira Y., Asada A., Fujinori M., Fujita M., Funae Y.: Metabolism of lidocaine by purified rat liver microsomal cytochrome P-450 isozymes. Biochem. Pharmacol., 1989, 38, 4439-4444.
21. Rick A.F., Belpaire F.M., Dello C., Bogaert M.G.: Influence of enhanced alpha-1-acid glycoprotein concentration on protein binding pharmacokinetics and antiarrhythmic effect of lidocaine in the dog. J. Pharmacol. Exp. Ther., 1987, 241, 289-293.
22. Sato H., Terasaki T., Okumura K., Tsuji A.: Effect of receptor up-regulation on insulin pharmacokinetics in streptozotocin-treated diabetic rats. Pharm. Res., 1991, 8, 563-569.
23. Shimojo N., Ishizaki T., Imaoka S., Funae Y., Fujii S., Okuda K.: Changes in amounts of cytochrome P450 isoenzymes and levels of catalytic activities in hepatic and renal microsomes of rats with streptozotocin-induced diabetes. Biochem. Pharmacol., 1993, 46, 621-627.
24. Thomson A.H., Elliot H.L., Kelman AW., Meredith P.A., Whiting B.: The pharmacokinetics and pharmacodynamics of lignocaine and MEGX in healthy subjects. J. Pharmacokinet. Biopharm., 1986, 15, 101-114.
25. Thummel K.E., Schenkman J.B.: Effects of testosterone and growth hormone treatment on hepatic microsomal P450 expression in the diabetic rats. Mol. Pharmacol., 1990, 37, 119-129.
26. Wang J.S., Backman J.T., Wen X., Taavitsainen P., Neuvonen P.J., Kivisto KT.: Fluvoxamine is a more potent inhibitor of lidocaine metabolism than ketoconazole and erythromycin in vitro. Pharmacol. Toxicol., 1999, 95, 201-205.
27. Warren B.L., Pak R., Finlayson M., Gontownick L., Suanhara G., Bessward G.: Differential effects of diabetes on microsomal metabolism of various substrates. Biochem. Pharmacol., 1983, 32, 327-335.
28. Wilkinson G.R., Shand D.G.: A physiological approach to hepatic drug clearance. Clin. Pharmacol. Ther., 1975, 18, 377-385.